Top Markets
Coin of the day
RegeneRx Biopharmaceuticals, Inc. RegeneRx Biopharmaceuticals, Inc.

RegeneRx Biopharmaceuticals, Inc.

RGRX
株式のランク #42502
RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the... RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the advancement of therapeutic peptides, with a primary emphasis on thymosin beta 4, engineered for the protection, repair, and regeneration of tissues and organs. The company's development pipeline includes RGN-259, a preservative-free ophthalmic solution designed to restore corneal tissues following injury, disease, or other pathologies; RGN-352, an injectable formulation under investigation for its potential in treating cardiovascular ailments, central and peripheral nervous system disorders, and various other medical conditions; and RGN-137, a topical gel aimed at accelerating the healing of skin wounds and minimizing scar tissue. Strategic alliances have been forged with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. Incorporated in 1982, the company initially operated as Alpha 1 Biomedicals, Inc., adopting the name RegeneRx Biopharmaceuticals, Inc. in 2000. Its operations are headquartered in Rockville, Maryland.
株価
$0.0007
最終同期: 2026-08-11
時価総額
$1.05K
変化(1日)
0.00%
変化(1年)
250.00%
US
取引 RegeneRx Biopharmaceuticals, Inc. (RGRX)

カテゴリー

RegeneRx Biopharmaceuticals, Inc.(RGRX)の配当履歴
RegeneRx Biopharmaceuticals, Inc.(証券コード:RGRX)は合計で0回の配当を行いました。
すべての配当の合計(株式分割調整済み)は:0.00
配当利回り(TTM):0
2026から2026までのRegeneRx Biopharmaceuticals, Inc.(RGRX)の配当履歴
年間配当支払い
配当(株式分割調整済み) 変化
提供された日付のデータは十分ではありません。
すべての配当支払いの一覧
配当 変化
提供された日付のデータは十分ではありません。
同業他社や競合企業の配当履歴